Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392323 · ClinicalTrials.gov registry record · NA
Incidence of COVID-19 Test Conversion in Post-surgical Patients
A NA study of SARS-CoV-2, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 111
- Enrollment target
- 2
- Study locations
NCT04392323: Completed NA study of SARS-CoV-2, sponsored by Northwell Health.
NCT04392323 is a NA study of SARS-CoV-2 that has completed, run by Northwell Health. The registered enrollment target is 111 participants, below the 3,451-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04392323, a NA study of SARS-CoV-2, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 111 participants
- Enrollment target
- 2
- Study locations
Study Summary
The current Sars-CoV-2 (COVID-19) pandemic has created major changes in how physicians perform routine healthcare for our patients, including elective and non-elective surgical procedures. Beginning on March 16th, 2020 Northwell Health postponed all elective surgeries. As the incidence of COVID-19 cases begins to decrease and hospital volume improves we need to ensure the safety of our patients planning surgical procedures. However, at this time there is a scarcity of data regarding the COVID-19 test conversion rate in surgical patients. Our goal is to determine the COVID-19 test conversion rate in these patients to better guide strategies for restarting surgical care in a large-scale pandemic. Patients will be routinely tested with serology and PCR for COVID-19 24-48 hours prior to their scheduled surgery. Those who provide informed consent will be re-tested 12-16 days after discharge from the hospital to determine any potential nosocomial infection rate. Patients will also answer a few questions during their retest to allow the study team to gauge exposure risk postoperatively after leaving the hospital.
Primary Outcome
Patients that have negative pre-operative testing that convert to positive testing 14 days post-discharge
Conditions Studied
Interventions
- DIAGNOSTIC_TEST COVID-19 PCR and Serology
Study Locations (2)
New York
- North Shore University Hospital - Manhasset
- Long Island Jewish Medical Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2020-05-13 |
| Est. Completion | 2020-10-04 |
| Phase | NA |
What the finished NCT04392323 record still lists
NCT04392323 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 3,451-participant average among 34 other SARS-CoV-2 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 1 intervention - of which COVID-19 PCR and Serology is the first listed.
NCT04392323 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04392323 about?
NCT04392323 is a clinical study titled "Incidence of COVID-19 Test Conversion in Post-surgical Patients". The current Sars-CoV-2 (COVID-19) pandemic has created major changes in how physicians perform routine healthcare for our patients, including elective and non-elective surgical procedures. Beginning on March 16th, 2020 Northwell Health postponed all elective surgeries. As the incidence of COVID-19 c...
What is the current status of trial NCT04392323?
This trial is currently completed. It is a NA study. The enrollment target is 111 participants. The study started on 2020-05-13. Estimated completion is 2020-10-04.
What conditions does trial NCT04392323 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT04392323?
The interventions under investigation include: COVID-19 PCR and Serology (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04392323?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04392323 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04392323's enrollment target sits among peer trials
111 26th of 34 higher than 9 of 34 other SARS-CoV-2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other SARS-CoV-2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving the Collaborative Health of Minority COVID-19 Survivor and Carepartner Dyads
RECRUITING · NA
-
NOWDx Test for the Detection of Antibodies to COVID-19
COMPLETED · NA
-
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
COMPLETED · NA
-
A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests
COMPLETED · NA
-
Rapid, Onsite COVID-19 Detection
COMPLETED · NA
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI